Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $10.00 by Analysts at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX) had its price objective decreased by equities researchers at BTIG Research to $10.00 in a research note issued to investors on Friday, MarketBeat reports. The firm currently has a “buy” rating on the stock. BTIG Research‘s target price indicates a potential upside of 45.54% from the stock’s previous close.

A number of other analysts have also recently weighed in on AVTX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Guggenheim restated a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. Finally, Leerink Partners initiated coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Avalo Therapeutics has an average rating of “Moderate Buy” and an average price target of $39.10.

Avalo Therapeutics Trading Down 7.8%

NASDAQ AVTX traded down $0.58 on Friday, hitting $6.87. 522,633 shares of the stock traded hands, compared to its average volume of 1,267,759. The stock has a 50-day moving average of $16.30 and a 200 day moving average of $16.67. Avalo Therapeutics has a twelve month low of $6.80 and a twelve month high of $24.27. The company has a market capitalization of $368.49 million, a P/E ratio of -1.58 and a beta of 0.68.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, equities research analysts expect that Avalo Therapeutics will post -2.95 earnings per share for the current year.

Insider Transactions at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at approximately $651,567. This trade represents a 23.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 24,258 shares of company stock worth $415,434. Company insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Braidwell LP bought a new stake in shares of Avalo Therapeutics during the 2nd quarter worth $30,107,000. Seven Fleet Capital Management LP boosted its stake in shares of Avalo Therapeutics by 806.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after acquiring an additional 510,540 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after acquiring an additional 507,960 shares in the last quarter. DV Trading LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter worth $5,376,000. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares in the last quarter. 87.06% of the stock is owned by institutional investors.

More Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Wedbush maintained an “outperform” rating while lowering its price target from $34 to $22. The revised target still implies substantial upside from recent trading levels. Wedbush Adjusts Avalo Therapeutics Price Target
• Positive Sentiment: BTIG Research retained a “buy” rating and set a $10 price target, indicating potential upside despite reducing its valuation expectations. BTIG Research Avalo Therapeutics Ratings
• Neutral Sentiment: Guggenheim reaffirmed its “neutral” rating, suggesting limited conviction in the near-term risk-reward profile. Guggenheim Avalo Therapeutics Ratings
• Neutral Sentiment: Trading in AVTX was temporarily paused under a limit-up/limit-down (LULD) volatility halt, highlighting unusually sharp trading activity but not representing a fundamental company announcement.
• Negative Sentiment: HC Wainwright downgraded Avalo from “buy” to “neutral,” while separately reaffirming a neutral rating in another update. The change signals reduced confidence in the stock’s near-term appreciation potential. HC Wainwright Downgrades Avalo Therapeutics
• Negative Sentiment: Analysts also cut price targets, including Wedbush’s reduction, reflecting lower valuation assumptions. Reports that AbbVie’s phase 3 HS results may strengthen a competing treatment add a significant pipeline and commercialization risk for Avalo. AbbVie Phase 3 Data Subdue Avalo Shares

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.